Teva, AbbVie Face Certified Class Over Niaspan Pay-For-Delay
A group of direct buyers of the cholesterol drug Niaspan scored a victory on Wednesday when a Pennsylvania federal judge approved their bid to move forward as a class with a...To view the full article, register now.
Already a subscriber? Click here to view full article